Skip to main content

Advertisement

Table 6 ANN prediction based on 30 blinded samples in the melanoma data set

From: A simpler method of preprocessing MALDI-TOF MS data for differential biomarker analysis: stem cell and melanoma cancer studies

  50 ANN sub-models     
Sample label S2 S3 ANN output Std err in 95% CI ANN classification Target output
Blind 1 50 0 0 0 S2 S2
Blind 2 50 0 0 0 S2 S2
Blind 3 50 0 0 0 S2 S2
Blind 4 50 0 0 0 S2 S2
Blind 5 0 50 1 0 S3* S2
Blind 6 40 10 0.200 0.115 S2 S2
Blind 7 50 0 0 0 S2 S2
Blind 8 50 0 0 0 S2 S2
Blind 9 46 4 0.080 0.078 S2 S2
Blind 10 50 0 0 0 S2 S2
Blind 11 42 8 0.160 0.106 S2 S2
Blind 12 47 3 0.060 0.069 S2 S2
Blind 13 50 0 0 0 S2 S2
Blind 14 49 1 0.020 0.040 S2 S2
Blind 15 0 50 1 0 S3* S2
Blind 16 0 50 1 0 S3 S3
Blind 17 0 50 1 0 S3 S3
Blind 18 0 50 1 0 S3 S3
Blind 19 0 50 1 0 S3 S3
Blind 20 0 50 1 0 S3 S3
Blind 21 5 45 0.900 0.087 S3 S3
Blind 22 0 50 1 0 S3 S3
Blind 23 0 50 1 0 S3 S3
Blind 24 5 45 0.900 0.087 S3 S3
Blind 25 0 50 1 0 S3 S3
Blind 26 0 50 1 0 S3 S3
Blind 27 0 50 1 0 S3 S3
Blind 28 0 50 1 0 S3 S3
Blind 29 0 50 1 0 S3 S3
Blind 30 0 50 1 0 S3 S3
  1. S2 refers to the stage 2 of melanoma. S3 is the stage 3 of melanoma. ANN output is computed based on the average performance from 50 random samplings. Std err with 95% CI refers to the standard error for ANN output in 95% confident interval range. ANN classification indicates the final outcome of the model. Target output refers to the original group to which the sample belongs to.